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ABSTRACT
....................................................................................................................................................
The Crohn’s and Colitis Foundation of America Partners Patient-Powered Research Network (PPRN) seeks to advance and accelerate comparative
effectiveness and translational research in inflammatory bowel diseases (IBDs). Our IBD-focused PCORnet PPRN has been designed to overcome
the major obstacles that have limited patient-centered outcomes research in IBD by providing the technical infrastructure, patient governance, and
patient-driven functionality needed to: 1) identify, prioritize, and undertake a patient-centered research agenda through sharing person-generated
health data; 2) develop and test patient and provider-focused tools that utilize individual patient data to improve health behaviors and inform health
care decisions and, ultimately, outcomes; and 3) rapidly disseminate new knowledge to patients, enabling them to improve their health. The
Crohn’s and Colitis Foundation of America Partners PPRN has fostered the development of a community of citizen scientists in IBD; created a portal
that will recruit, retain, and engage members and encourage partnerships with external scientists; and produced an efficient infrastructure for
identifying, screening, and contacting network members for participation in research.
....................................................................................................................................................
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INTRODUCTION
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel
diseases (IBDs) that affect approximately 1.4 million individuals in the
United States,1 cost over $6 billion annually,2 and cause substantial
patient morbidity,3,4 missed work5 and school,6 and diminished quality
of life.7,8 Fortunately, rapid discovery of the genetic, immunological,
and microbiome-related factors involved in disease pathogenesis has
resulted in an increasing number of new treatment options now avail-
able to patients. However, translating new treatments into improved
patient-centered care and outcomes will require robust comparative
effectiveness (and safety) research. Moreover, combining comparative
effectiveness research with translational research will ultimately usher
an era of “personalized medicine” in which patients, caregivers, and
clinicians make collaborative choices based upon patient preferences
and strong and individualized evidence regarding disease prognosis,
treatment effectiveness and safety, and response to therapy. For this
reason, comparative effectiveness research in IBD has been recog-
nized by the Institute of Medicine and the Agency for Healthcare
Research and Quality as a top national priority.9
In response to the growing need for comparative effectiveness and
translational research in IBD, the Crohn’s and Colitis Foundation of
America (CCFA), the nation’s leading IBD patient support, research,
and advocacy foundation, launched the CCFA Partners internet-based
cohort study in 2011. CCFA Partners was designed to study the ef-
fects of treatment, diet, and other lifestyle factors on patient-reported
and other disease outcomes, while simultaneously establishing a
technological platform and patient base to support a variety of clinical
and translational studies. In 2014, with funding from the Patient
Centered Outcomes Research Institute (PCORI), we began to leverage
this infrastructure to transform the cohort study into a Patient-
Powered Research Network (PPRN), in conjunction with PCORnet, a
National Patient-Centered Clinical Research Network, which seeks to
advance the nation’s capacity to conduct comparative effectiveness
research. PCORnet is composed of Clinical Data Research Networks,
which are based on electronic health records of large populations re-
ceiving health care within integrated/networked delivery systems, and
PPRNs built by communities of motivated patients partnering with
researchers.10
The CCFA Partners PPRN is built around a novel Internet cohort of
14 200 IBD patients and focuses on patient-reported exposures,
health behaviors, and outcomes.11 Our team partners with industry
leaders: Crohnology (the leading IBD social network), Validic (an inno-
vative cloud-based platform that connects person-generated data
from devices, apps, and wearables to third-party platforms), and
Patients Know Best (personal health record vendor) to integrate per-
son-generated health data (PGHD) from mobile health applications,
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wearables, social networks, and personal health records. The overall
objectives of the CCFA Partners PPRN are to: 1) enhance network
growth, diversity, and retention; 2) build a robust network commu-
nity, including patient governance structures that allow greater in-
volvement of patients in research; 3) expand the network data
system to include electronic health records, data from mobile health
applications (apps) and wearables, and biological samples; 4) de-
velop a customized, scalable, and adaptable distributed data net-
work; 5) develop and test patient- and provider-focused tools that
utilize individual patient data to improve health behaviors, health care
decisions, and, ultimately, outcomes; 6) further engage the scientific
community through open collaboration and data sharing; and 7) rap-
idly disseminate new knowledge back to patients, enabling them to
improve their health.
INFORMATICS INFRASTRUCTURE
PPRN Architecture.
Our PPRN’s informatics architecture utilizes a distributed data model
to support the data sharing and integration needs of our PPRN and so
Figure 1: PPRN Architecture.
Apache Object-Oriented Data Technology (OODT) connects distributed, heterogeneous data sources. Data handling and analysis tools use
Applied Programming Interfaces to connect the virtual data warehouse and access the PPRN. PKB¼ Patients Know Best; Croh
UI¼ Crohnology User Interface.
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that it is scalable, flexible, and adaptable to support future expansion
and functionalities (see Figure 1). Our approach centers upon meeting
the functional needs of both patient members and the research com-
munity, and ensuring that patients have control over their own data,
how it is used, and for what purpose. The interactive patient portal is
our patient-facing application where patients can complete survey
questionnaires; interact with their data and other members; and sub-
mit, discuss, and vote on research priorities.
Our PPRN informatics infrastructure leverages open source meth-
ods and technology developed by the National Aeronautics and Space
Administration and subsequently delivered to the Apache Software
Foundation. Apache Object-Oriented Data Technology (OODT) is the
core technology that creates our “virtual” data warehouse, which
allows all data to remain stored at its point of capture, unlike a data
warehousing approach that moves and consolidates all data centrally.
Apache Object-Oriented Data Technology was customized to integrate
PPRN data resources: 1) CCFA Partners surveys, which include pa-
tient-reported outcomes; 2) wearable and smartphone application data
brought in through Validic; 3) Crohnology data; 4) Patients Know Best
personal health record data; and 5) frequent short surveys (“check-
ins”) administered directly on the PPRN portal. Apache Object-
Oriented Data Technology maps and translates data according to our
evolving PPRN data model and returns, in real time, an integrated data
set to end users (e.g., an individual CCFA Partners member or
researcher).
Standardized data elements and vocabularies.
CCFA Partners collects standardized, patient-reported data through
core Internet surveys every 6 months. The core surveys consist of
questions in the following categories: 1) contact information; 2) demo-
graphics including age, gender, race/ethnicity, educational status,
etc.; 3) disease characteristics including disease type and clinical
characteristics, family history of IBD, surgical history, hospitalization
history, cancer history, etc.; 4) health behaviors including medication
use, adherence, smoking, etc.; and 5) disease outcomes, including
current disease-related symptoms, quality of life assessments, and
other patient reported outcomes (PROs). In addition to these core sur-
veys, CCFA Partners also implements ad-hoc surveys on specific
topics as required to support investigator-initiated research studies.
To the extent possible, survey items are based on validated instru-
ments. We deliberately include measures that are both general
(National Institutes of Health Patient Reported Outcome Measurement
Information System) and disease-specific (Short CD Activity Index,
Short Clinical Colitis Index, and Short IBD Questionnaire). Using the
CCFA Partners portal, additional patient-reported data is now collected
from smartphones and wearable devices, personal health record data,
and short surveys. Our patient governance council members helped
guide the selection of measures.
Across all data sources, we are building and expanding a PPRN
ontology that uses existing international standards that, ultimately, will
include the following components: medications (RXNorm including
National Drug Code and Anatomical Therapeutic Chemical
Classification System (ATC)), diagnoses (International Classification of
Diseases: ICD-9 and ICD-10), procedures (Current Procedural
Terminology, ICD-9 Clinical Modification procedure, Healthcare
Common Procedure Coding System), laboratory data (Logical
Observation Identifiers Names and Codes or LOINC), pathology data
(Systematized Nomenclature of Medicine or SNOMED), and dietary in-
formation (U.S. Department of Agriculture Nutrient Database for
Standard Reference). The CCFA Partners PPRN ontology is mapped to
the PCORnet Common Data Model where applicable.
PATIENT-CENTERED DESIGN
The design of our network has been informed by qualitative research,
including focus groups and one-on-one interviews. To further incorpo-
rate the patient voice, we assembled a 5-member Patient Governance
Council that has been involved in all aspects of the design process, in-
cluding prioritization of portal functionalities, drafting the written con-
tent of the patient portal, reviewing all survey items, and identifying
relevant patient-reported outcomes. Additionally, our lead software de-
veloper for the patient portal is a patient with IBD.
CCFA PARTNERS PPRN INTERACTIVE PATIENT PORTAL
Our PPRN’s patient portal seeks to be a “home base” for IBD patients
where they can record, contribute, and use their PGHD for self-
management and discovery (see Supplemental Figure 1). A brief video
for potential members (IBD patients and researchers) that introduces
the vision and mission of our PPRN can be viewed on the home page
of our portal at www.ccfapartners.org.
During enrollment, patients sign an online informed consent form
indicating their willingness to provide PGHD through biannual surveys
or directly on our PPRN portal. For each device linked or each addi-
tional data stream, there is a separate brief consent by which users
can approve the use of this additional data for conducting research.
Members can unenroll from the study or opt out of an entire survey or
any specific section or question at any time. Similarly, members can
disconnect a device/data source at any time. They can also choose to
participate in research prioritization functionality or not, and patients
can withdraw from study at any time. When a member withdraws, we
retain their data but do not initiate any further contact for follow-up,
and this is disclosed to members during the consent process.
Members can interface with our PPRN portal using any number of
devices and platforms (desktop or mobile, iOS, Android, etc.) such that
it can be viewed using the platform/device most convenient to them.
Members are able to create a social profile and choose whether it will
be shared or private, and whether they want to engage in a commu-
nity of IBD patients.
Our PPRN collects standardized PROs data at enrollment and then
every 6 months, collects short assessments to “check in” about how
they are feeling that day, and asks 3 additional symptom questions
about the previous 7 days. Members can also enter and update their
current medications.
Additionally, patients can connect popular smartphone applications
like Moves and wearables like Fitbit to their portal accounts. Members
sync their applications and wearable devices using Bluetooth technol-
ogy to the respective application/device’s platforms (i.e., a Fitbit Zip
would sync to the Fitbit app) and Validic’s API allows us to bring the
data into the PPRN portal. Our goal is to capture observations of daily
living through these mobile health apps and wearables so that patients
can continuously add their own experiences and knowledge to enrich
our database of PGHD.
The portal is also a medium through which the research team can
communicate new research discoveries. Members can see in real
time who used their data, for what purpose, and the results of their
data contributions.
In the My Health Data section of our patient portal, patients can view
a series of reports (My Trends, My Measures, and My Dashboard) that
integrates multiple types of PGHD (surveys/PROs, mobile health apps,
and wearables) to provide summaries of their data that can be used to
better understand and monitor trends and gain insights that may help
them to manage their symptoms and health, and to facilitate compari-
sons to aggregate member data across the network and to norms es-
tablished from aggregate data. For example, a patient may see whether
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walking more steps/day has improved their disease activity scores over
time. Users can also view My Measures, which displays their PROs data
such as fatigue or disease activity in relation to established norms
among IBD patients (see Figure 2). They can also see a snapshot of key
data such as physical activity, sleep, and disease activity in their My
Dashboard (see Supplemental Figure 2).
CROWDSOURCING FOR RESEARCH PRIORITIZATION
Our PPRN is grounded in the philosophy that the most important pa-
tient-centered research topics will come from patients living with IBD.
Our mission is to cultivate a community of “citizen scientists” who not
only envision impactful research questions, but also accelerate IBD
comparative effectiveness research through their PGHD contributions.
Our members propose their own research ideas, can discuss these
ideas and the research issues that are most important to them, and
can vote on research topics proposed by peers so that prioritization is
crowd-sourced from our members (see Supplemental Figure 3). The
research team, which includes patients, then reviews high-priority
topics and disseminates these to the broad IBD research community.
We also designed a virtual badge-based rewards system to foster
engagement and excitement around contributing PGHD to the PPRN’s
research efforts. Members earn “Citizen Scientist” points for complet-
ing daily/weekly survey questionnaires and bi-annual questionnaires,
for connecting their smartphone applications and wearables, and for
submitting and voting on research topics (see Figure 3).
RECRUITMENT AND ENROLLMENT
Thus far, our PPRN has enrolled 14 200 members (1% of the US
IBD population) from all 50 United States. To date, much of the net-
work growth (10 000 members) has been attributed to CCFA email
campaigns. We have also employed a grass-roots approach to further
increase enrollment and have engaged 40 local CCFA chapters to
promote the PPRN during their educational and fundraising events.
Indeed, an important lesson learned from this work is the importance
of partnering with one or more national advocacy groups. To stimulate
network enrollment, we launched a multimedia campaign in connec-
tion with the launch of our interactive patient portal in February 2015
(press release, promotional videos, email campaigns, IBD blogger
publicity, and social media). Our future growth plans include cross-fer-
tilization with other multicenter cohort studies in which participants
will be invited to join our PPRN.
NETWORK MEMBERSHIP AND ENGAGEMENT
Members are mostly between the ages of 18–64 years old with a
mean age of 43 years, female, white, and educated (see Table 1). The
racial and ethnic demographics of IBD in the United States are largely
unknown, and therefore it is not possible to fully assess the represen-
tativeness of the CCFA Partners membership. Within the limited data
that is available, data suggests that the racial and ethnic composition
of patients with IBD is somewhat different than the general US popula-
tion. Compared to the white population, IBD affects a lower proportion
of Blacks (Odds Ratio 0.4), Hispanics (Odds Ratio 0.2), and Asians
(Odds Ratio 0.3).12 Nevertheless, because our cohort does not include
patients without Internet access or with low levels of education/liter-
acy, our membership may slightly underrepresent minority populations
with IBD. Given the importance of increasing diversity, our PPRN will
be focusing on minority recruitment, and we have recently conducted
a focus group to better inform these efforts.
Long-term follow up is an essential component of all cohort stud-
ies and particularly in studies of chronic conditions, such as IBD. CCFA
Partners collects longitudinal follow-up data through biannual surveys,
along with other recently-added methods of obtaining PGHD as
Figure 2: Screenshot of My Measures section.
This shows an example of data displays of PRO data on pain
interference and quality of life.
Figure 3: Screenshot of the Badges Earned Section.
This shows an individual CCFA Partners PPRN member’s con-
tributions to Research (Survey Responder, Check-iner, Voter,
Discusser, Community Face, Citizen Scientist.) Amber R. is a
part of our research team and this does not show actual pa-
tient data.
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described above. Nearly all members (89%) have completed baseline
surveys. Sixty-four percent of members who have been enrolled for
6 months or longer have completed 1 or more follow-up surveys. Over
2300 members have contributed patient reported data for > 3.5 years.
The total follow-up time in our PPRN is over 21 300 person-years
(mean length of follow up is 1.5 years). Supplemental Figure 4 pro-
vides a graphical illustration of the distribution of follow-up time in our
PPRN. From July to December 2014, the response rate to follow-up
surveys sent to active members was 76%. Patients have contributed
14 862 509 data elements across 36 content areas from 47 174 sur-
veys, and all have signed consent indicating their willingness to be
contacted for future research studies.
Our PPRN members have proposed 67 research questions and
there are currently 12 research ideas being studied. Eight hundred
and seventeen votes have been cast for proposed research ideas with
the most votes (123) cast thus far for: “We should compare individuals
who manage their disease with medication and those who manage
their disease with popular diets within the IBD community.”
PARTNERSHIPS, COLLABORATIONS, AND RESEARCH
PRODUCTIVITY
Our PPRN has an open and transparent process for collaborating with
external researchers. Our “For Researchers” website contains: 1) a
summary of past, current, and proposed studies; 2) a data dictionary;
3) instructions and timelines for submitting study proposals; and 4) an
overview of the cost structure. All study submissions are reviewed by
patients and scientists. To date, we have received 37 research study
proposals from outside investigators and 20 have been approved by
our PPRN Project Selection Committee.
Our network also has a proven track record for undertaking epide-
miological, translational, and interventional research, having already
produced 11 peer-reviewed scientific papers11,13–20 and 25 abstracts,
with several additional studies underway. Representative examples of
ongoing or completed PPRN research includes: 1) a cross-sectional
and longitudinal validation of Patient Reported Outcome Measurement
Information System measures in IBD16, 2) several longitudinal studies
evaluating the impact of lifestyle factors on IBD disease course21,22, 3)
a feasibility study to establish best practices and evaluate response
rates for bio-banking among PPRN members, 4) a PCORI-funded study
to evaluate patient preferences for competing treatment options
among IBD patients, and 5) targeted recruitment for independent clini-
cal and translational studies.
Although the CCFA Partners PPRN has been developed to facilitate
epidemiological, clinical, and translational research in IBD, this model
is broadly applicable to research in other chronic conditions. Indeed,
Phase I of PCORnet consisted of 17 other PPRNs with whom our net-
work has collaborated and shared best practices and lessons learned
over the past 18 months. We anticipate that, in the future, collabora-
tion and resource sharing across PPRNs will accelerate the efficiency
and pace of network development. As the PPRN matures, facilitating
and sustaining engagement with the portal will be critical. Continuous
feedback from our membership will allow us to solicit and gauge
which features and functionalities are the most useful to patients.
Additionally, we must ensure that our members’ data and privacy are
safeguarded appropriately and that any potential conflicts of interest
are disclosed transparently. Patient input during the formative stages
of the PPRN were vital to shaping our engagement and governance
strategies, and we believe that the continued involvement from our
members will be important to help our PPRN be flexible in meeting
members’ needs.
CONCLUSION
Our CCFA Partners PPRN engages patients and researchers to collabo-
ratively advance comparative effectiveness research through enriching
existing research datasets with PGHD. Future steps include further col-
laborations with PCORnet Clinical Data Research Networks and en-
hancing user-centered interactive data displays to help patients
harness PGHD and transform their PGHD into knowledge and insights
that help them manage their IBD, symptoms, and overall health.
We believe that leveraging technologies to create a community of en-
gaged patients and facilitate the collection and sharing of PGHD is a
model that may be broadly applicable to many chronic conditions.
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